#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA3883092	Functional	Agonist activity at human recombinant EP3A receptor expressed in HEK293 cells assessed as effect on calcium accumulation by Fluo-4 AM dye based FLIPR assay	Homo sapiens	114	ALA3882734	cell-based format	Patent Bioactivity Data
2.	ALA3883093	Binding	Displacement of [3H]PGE2 from from human EP2 receptor expressed in HEK293 cells at pH 7.3 membranes incubated for 60 mins	Homo sapiens	55	ALA3882734	cell-based format	Patent Bioactivity Data
3.	ALA3883096	Functional	Agonist activity at human recombinant FP receptor expressed in HEK293 cells assessed as effect on calcium accumulation by Fluo-4 AM dye based FLIPR assay	Homo sapiens	96	ALA3882734	cell-based format	Patent Bioactivity Data
4.	ALA3883097	Functional	Agonist activity at human recombinant EP1 receptor expressed in HEK293 cells assessed as effect on calcium accumulation by Fluo-4 AM dye based FLIPR assay	Homo sapiens	95	ALA3882734	cell-based format	Patent Bioactivity Data
5.	ALA3883098	Functional	Agonist activity at human recombinant EP2 receptor expressed in HEK293 cells assessed as effect on calcium accumulation by Fluo-4 AM dye based FLIPR assay	Homo sapiens	140	ALA3882734	cell-based format	Patent Bioactivity Data
6.	ALA3883100	Functional	Agonist activity at human recombinant TP receptor expressed in HEK293 cells assessed as effect on calcium accumulation by Fluo-4 AM dye based FLIPR assay	Homo sapiens	114	ALA3882734	cell-based format	Patent Bioactivity Data
7.	ALA3883101	Functional	Agonist activity at human recombinant IP receptor expressed in HEK293 cells assessed as effect on calcium accumulation by Fluo-4 AM dye based FLIPR assay	Homo sapiens	114	ALA3882734	cell-based format	Patent Bioactivity Data
8.	ALA3883102	Functional	Agonist activity at human recombinant DP receptor expressed in HEK293 cells assessed as effect on calcium accumulation by Fluo-4 AM dye based FLIPR assay	Homo sapiens	112	ALA3882734	cell-based format	Patent Bioactivity Data
9.	ALA3883113	Functional	Reduction in intraocular pressure in Beagle dog assessed as maximal change in intraocular pressure at 0.3% administered topically to one eye immediately after first intraocular pressure reading by pneumatonometry	Canis lupus familiaris	3	ALA3882734	tissue-based format	Patent Bioactivity Data
10.	ALA3883114	Functional	Effect on ocular surface hyperemia in Beagle dog assessed as maximum ocular surface hyperemia score assigned value at 0.3% administered topically to one eye immediately after first intraocular pressure reading by pneumatonometry	Canis lupus familiaris	3	ALA3882734	tissue-based format	Patent Bioactivity Data